• 1. Synthesis of silicon heterocycles via gas-phase silylium ion reactions with cyclic acetals and ketals??
  Weiguo A. Tao,Feng Wang,Jeffry W. Denault,R. Graham Cooks J. Chem. Soc. Perkin Trans. 2 1999 2325
• 2. Unusual dielectric response of 4-methyl-1,3-dioxolane derivatives
  Marzena Rams-Baron,Agnieszka J?drzejowska,Mateusz Dulski,Kamila Wolnica,Korbinian Geirhos,Peter Lunkenheimer,Marian Paluch Phys. Chem. Chem. Phys. 2018 20 28211
• 3. Unusual dielectric response of 4-methyl-1,3-dioxolane derivatives
  Marzena Rams-Baron,Agnieszka J?drzejowska,Mateusz Dulski,Kamila Wolnica,Korbinian Geirhos,Peter Lunkenheimer,Marian Paluch Phys. Chem. Chem. Phys. 2018 20 28211
• 4. Design of a solid catalyst for the synthesis of a molecule with blossom orange scent
  M. J. Climent,A. Velty,A. Corma Green Chem. 2002 4 565
• 5. Design of a solid catalyst for the synthesis of a molecule with blossom orange scent
  M. J. Climent,A. Velty,A. Corma Green Chem. 2002 4 565

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Dioxolanes 1,3-dioxolanes
• Solvents and Organic Chemicals Organic Compounds Acids/Esters
• Solvents and Organic Chemicals Organic Compounds Hydrocarbons

Recent Advances in the Application of 4-Methyl-1,3-dioxolane (CAS: 1072-47-5) in Chemical Biology and Pharmaceutical Research

4-Methyl-1,3-dioxolane (CAS: 1072-47-5) is a versatile cyclic acetal compound that has garnered significant attention in chemical biology and pharmaceutical research due to its unique structural properties and reactivity. Recent studies have explored its potential as a building block in drug synthesis, a solvent in pharmaceutical formulations, and a precursor for bioactive molecules. This research brief synthesizes the latest findings on the applications and mechanistic insights of 4-Methyl-1,3-dioxolane, with a focus on its role in advancing therapeutic development.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 4-Methyl-1,3-dioxolane as a key intermediate in the synthesis of novel antiviral agents. Researchers utilized its cyclic acetal moiety to enhance the metabolic stability of nucleoside analogs, resulting in compounds with improved pharmacokinetic profiles. The study highlighted the compound's ability to modulate drug solubility and bioavailability, making it a valuable tool in prodrug design.

In the realm of drug delivery systems, a team at MIT reported in Advanced Materials (2024) on the development of 4-Methyl-1,3-dioxolane-based responsive polymers. These materials exhibited pH-dependent degradation properties, enabling targeted release of chemotherapeutic agents in tumor microenvironments. The research underscored the compound's potential in creating smart drug carriers with tunable release kinetics.

Recent toxicological assessments (Regulatory Toxicology and Pharmacology, 2024) have provided updated safety profiles for 4-Methyl-1,3-dioxolane, addressing concerns about its use in pharmaceutical applications. The comprehensive study established NOAEL (No Observed Adverse Effect Level) values and characterized metabolic pathways, supporting its safe incorporation in medicinal chemistry workflows.

Emerging applications in biocatalysis have revealed novel enzymatic transformations involving 4-Methyl-1,3-dioxolane. A Nature Catalysis publication (2024) described engineered enzymes capable of stereoselective modifications of the dioxolane ring, opening new avenues for asymmetric synthesis of chiral pharmaceuticals.

The compound's role in green chemistry initiatives has also expanded, with several recent patents (2023-2024) describing sustainable production methods for 4-Methyl-1,3-dioxolane using biomass-derived feedstocks. These developments align with the pharmaceutical industry's increasing emphasis on environmentally benign synthetic routes.

Looking forward, ongoing clinical trials are investigating 4-Methyl-1,3-dioxolane-containing prodrugs for neurological disorders, with preliminary results expected in late 2024. Additionally, computational studies are providing deeper insights into structure-activity relationships, enabling more rational design of derivatives with enhanced therapeutic properties.

• 99569-11-6(Glycerol formal)
• 5464-28-8((1,3-Dioxolan-4-yl)methanol)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)